Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses

Xuanming Yang, Xunmin Zhang, May Lynne Fu, Ralph R. Weichselbaum, Thomas F. Gajewski, Yajun Guo, Yang Xin Fu

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Antibodies (Abs) that preferentially target oncogenic receptors have been increasingly used for cancer therapy, but tumors often acquire intrinsic Ab resistance after prolonged and costly treatment. Herein we armed the Ab with IFNβ and observed that it is more potent than the first generation of Ab for controlling Ab-resistant tumors. This strategy controls Ab resistance by rebridging suppressed innate and adaptive immunity in the tumor microenvironment. Mechanistically, Ab-IFNβ therapy primarily and directly targets intratumoral dendritic cells, which reactivate CTL by increasing antigen cross-presentation within the tumor microenvironment. Additionally, blocking PD-L1, which is induced by Ab-IFNβ treatment, overcomes treatment-acquired resistance and completely eradicates established tumors. This study establishes a next-generation Ab-based immunotherapy that targets and eradicates established Ab-resistant tumors.

Original languageEnglish (US)
Pages (from-to)37-48
Number of pages12
JournalCancer Cell
Volume25
Issue number1
DOIs
StatePublished - Jan 13 2014

Fingerprint

Tumor Microenvironment
Adaptive Immunity
Innate Immunity
Interferons
Neoplasms
Cross-Priming
Therapeutics
Antigen Presentation
Immunotherapy
Dendritic Cells
Antibodies
interferon-alpha 8

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. / Yang, Xuanming; Zhang, Xunmin; Fu, May Lynne; Weichselbaum, Ralph R.; Gajewski, Thomas F.; Guo, Yajun; Fu, Yang Xin.

In: Cancer Cell, Vol. 25, No. 1, 13.01.2014, p. 37-48.

Research output: Contribution to journalArticle

Yang, Xuanming ; Zhang, Xunmin ; Fu, May Lynne ; Weichselbaum, Ralph R. ; Gajewski, Thomas F. ; Guo, Yajun ; Fu, Yang Xin. / Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. In: Cancer Cell. 2014 ; Vol. 25, No. 1. pp. 37-48.
@article{3987ccc6e92f49b196ff3322bbd5964b,
title = "Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses",
abstract = "Antibodies (Abs) that preferentially target oncogenic receptors have been increasingly used for cancer therapy, but tumors often acquire intrinsic Ab resistance after prolonged and costly treatment. Herein we armed the Ab with IFNβ and observed that it is more potent than the first generation of Ab for controlling Ab-resistant tumors. This strategy controls Ab resistance by rebridging suppressed innate and adaptive immunity in the tumor microenvironment. Mechanistically, Ab-IFNβ therapy primarily and directly targets intratumoral dendritic cells, which reactivate CTL by increasing antigen cross-presentation within the tumor microenvironment. Additionally, blocking PD-L1, which is induced by Ab-IFNβ treatment, overcomes treatment-acquired resistance and completely eradicates established tumors. This study establishes a next-generation Ab-based immunotherapy that targets and eradicates established Ab-resistant tumors.",
author = "Xuanming Yang and Xunmin Zhang and Fu, {May Lynne} and Weichselbaum, {Ralph R.} and Gajewski, {Thomas F.} and Yajun Guo and Fu, {Yang Xin}",
year = "2014",
month = "1",
day = "13",
doi = "10.1016/j.ccr.2013.12.004",
language = "English (US)",
volume = "25",
pages = "37--48",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses

AU - Yang, Xuanming

AU - Zhang, Xunmin

AU - Fu, May Lynne

AU - Weichselbaum, Ralph R.

AU - Gajewski, Thomas F.

AU - Guo, Yajun

AU - Fu, Yang Xin

PY - 2014/1/13

Y1 - 2014/1/13

N2 - Antibodies (Abs) that preferentially target oncogenic receptors have been increasingly used for cancer therapy, but tumors often acquire intrinsic Ab resistance after prolonged and costly treatment. Herein we armed the Ab with IFNβ and observed that it is more potent than the first generation of Ab for controlling Ab-resistant tumors. This strategy controls Ab resistance by rebridging suppressed innate and adaptive immunity in the tumor microenvironment. Mechanistically, Ab-IFNβ therapy primarily and directly targets intratumoral dendritic cells, which reactivate CTL by increasing antigen cross-presentation within the tumor microenvironment. Additionally, blocking PD-L1, which is induced by Ab-IFNβ treatment, overcomes treatment-acquired resistance and completely eradicates established tumors. This study establishes a next-generation Ab-based immunotherapy that targets and eradicates established Ab-resistant tumors.

AB - Antibodies (Abs) that preferentially target oncogenic receptors have been increasingly used for cancer therapy, but tumors often acquire intrinsic Ab resistance after prolonged and costly treatment. Herein we armed the Ab with IFNβ and observed that it is more potent than the first generation of Ab for controlling Ab-resistant tumors. This strategy controls Ab resistance by rebridging suppressed innate and adaptive immunity in the tumor microenvironment. Mechanistically, Ab-IFNβ therapy primarily and directly targets intratumoral dendritic cells, which reactivate CTL by increasing antigen cross-presentation within the tumor microenvironment. Additionally, blocking PD-L1, which is induced by Ab-IFNβ treatment, overcomes treatment-acquired resistance and completely eradicates established tumors. This study establishes a next-generation Ab-based immunotherapy that targets and eradicates established Ab-resistant tumors.

UR - http://www.scopus.com/inward/record.url?scp=84892416698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892416698&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2013.12.004

DO - 10.1016/j.ccr.2013.12.004

M3 - Article

C2 - 24434209

AN - SCOPUS:84892416698

VL - 25

SP - 37

EP - 48

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 1

ER -